Monday, June 24, 2019

Matteo Costacurta, MD

Peter MacCallum Cancer Centre 
University of Melbourne
Melbourne, Australia

A genome-wide CRISPR screen identifies TOP2B as an acquired druggable vulnerability in the context of IMiD resistance” (Potential implications in multiple myeloma and lymphoma therapy)